Mercaptopurine Silver Pharma (Mercaptopurine Monohydrate)

After oral absorption, mercaptopurine is converted inside cells to thio‑inosine monophosphate, which blocks the synthesis of purine nucleotides. This inhibition reduces DNA and RNA production, limiting the proliferation of rapidly dividing cells, including leukemic lymphoblasts and activated immune cells involved in intestinal inflammation.

The dose of mercaptopurine is individualized and set by the prescribing clinician based on the patient’s age, weight, disease indication, and laboratory monitoring results. Dosage adjustments are made according to blood count and liver function tests to balance efficacy with safety.

Data on mercaptopurine use in pregnancy and lactation are limited. Because the drug can cross the placenta and is excreted in breast milk, it is generally avoided unless the potential benefit to the mother outweighs the possible risk to the fetus or infant. Decisions should be made in consultation with a specialist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Azathioprine is the most common alternative within the thiopurine class. Both drugs share a similar mechanism of inhibiting purine synthesis, but mercaptopurine is often preferred for acute lymphoblastic leukemia because of its more direct antineoplastic activity, whereas azathioprine is frequently used for long‑term immunosuppression in transplant and autoimmune settings.

Mercaptopurine tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

The medication is taken orally, usually with a glass of water. It may be prescribed with or without food, depending on the clinician’s guidance. Patients should follow the exact schedule provided by their healthcare professional and not alter the timing without medical advice.

The most critical risks include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity with possible liver failure, acute pancreatitis, and life‑threatening infections due to immunosuppression. Prompt medical attention is required if symptoms such as persistent fever, jaundice, severe abdominal pain, or unusual bleeding occur.

Mercaptopurine is contraindicated in individuals with known hypersensitivity to the drug or any thiopurine, in patients with severe bone‑marrow failure, and in those with active, uncontrolled infections. Caution is also advised for patients with significant hepatic or renal impairment, and it should be avoided in pregnant or breastfeeding women unless absolutely necessary.